Voclosporin

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are up more than 90% on Thursday after the company reported some positive Phase 3 data on a lupus treatment drug. Voclosporin in combination with mycophenolate and low-dose corticosteroids produced significantly higher kidney response rates in...

Shares of small-cap biotech Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) are on a tear after the company reported positive clinical readout for its lead asset voclosporin in treating lupus nephritis, an autoimmune disorder. Aurinia has a single-product pipeline. Voclosporin is being evaluated for...

Shares of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH), a clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity, ticked higher by more than 3 percent early Friday morning after the company presented results from an ongoing study. Aurinia presented remission...

Elemer Piros of Cantor Fitzgerald maintains an Overweight rating on Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)'s stock with a $14 price target after the company reported data from a Phase 2b study, which helped boost the stock higher by more than 5 percent. During the National Kidney Foundation...

Having demonstrated efficacy in its Phase 2b AURA-LV study for patients with active lupus nephritis, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)'s voclosporin appears “well-positioned in late-stage development to succeed,” Cantor Fitzgerald’s Elemer Piros said in a report. Piros...

Where offerings are concerned, IPOs take the cake, given the hype surrounding the events. Their lesser brethren, secondary offerings, do not attract as significant attention, often passed off as routine corporate affairs. What Are Secondary Offerings? A company does a second offering through...

On November 2, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) announced the successful completion of their end-of-Phase II meeting with the FDA and plans for a single Phase III clinical trial for fast-track-designated Voclosporin. Shares are up over 30 percent since then. There are an estimated 115,000...

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)'s Voclosporin is about to begin Phase 3 trials for first-line treatment of lupus nephritis. The company could be an “ideal acquisition candidate once Phase 3 kicks off,” Mackie Research Capital’s André Uddin said in a report. Uddin...

Shares of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH), a clinical-stage biopharmaceutical company that focuses in the field of nephrology and autoimmunity saw its stock soar by more than 35 percent Thursday morning. Aurinia announced Thursday morning data from a 24-week clinical study called...